A COMT gene haplotype associated with methamphetamine abuse

Pharmacogenetics and Genomics

Volumn 21, Issue 11, 2011, Pages 731-740

  Jugurnauth, Sarah K ^a   Chen, Chih Ken ^c,d   Barnes, Michael R ^b   Li, Tao ^a   Lin, Shih Ku ^e   Liu, Hsing Cheng ^e   Collier, David A ^a   Breen, Gerome ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

addiction; catechol O methyltransferase; COMT; haplotype; methamphetamine; microRNA; microRNA target prediction; substance abuse

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHAMPHETAMINE;

3' UNTRANSLATED REGION; COMPUTER MODEL; DOWN REGULATION; DRUG ABUSE; GENE DELETION; GENETIC ASSOCIATION; HAPLOTYPE; HUMAN; PRIORITY JOURNAL; PROTEIN RNA BINDING; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VELOCARDIOFACIAL SYNDROME;

ARMADILLO;

EID: 80054975644     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834a53f9     Document Type: Review

References (45)

1. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D, et al. Psychiatric symptoms in methamphetamine users. Am J Addict 2004; 13:181-190.
2. McKetin R, McLaren J, Lubman DI, Hides L. The prevalence of psychotic symptoms among methamphetamine users. Addiction 2006; 101: 1473-1478.
3. Glasner-Edwards S, Mooney LJ, Marinelli-Casey P, Hillhouse M, Ang A, Rawson R. Clinical course and outcomes of methamphetamine-dependent adults with psychosis. J Subst Abuse Treat 2008; 35:445-450.
4. Yui K, Ikemoto S, Ishiguro T, Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann N Y Acad Sci 2000; 914:1-12.
5. Van den Bree MB, Johnson EO, Neale MC, Pickens RW. Genetic and environmental influences on drug use and abuse/dependence in male and female twins. Drug Alcohol Depend 1998; 52:231-241.
6. Bousman CA, Glatt SJ, Everall IP, Tsuang MT. Genetic association studies of methamphetamine use disorders: a systematic review and synthesis. Am J Med Genet B Neuropsychiatr Genet 2009; 150B: 1025-1049.
7. Li T, Chen CK, Hu X, Ball D, Lin SK, Chen W, et al. Association analysis of the DRD4 and COMT genes in methamphetamine abuse. Am J Med Genet B Neuropsychiatr Genet 2004; 129B:120-124.
8. Tunbridge EM, Lane TA, Harrison PJ. Expression of multiple catechol-Omethyltransferase (COMT) mRNA variants in human brain. Am J Med Genet B Neuropsychiatr Genet 2007; 144B:834-839.
9. Zinkstok J, van Amelsvoort T. Neuropsychological profile and neuroimaging in patients with 22Q11.2 Deletion Syndrome: a review. Child Neuropsychol 2005; 11:21-37.
10. Tunbridge E, Burnet PW, Sodhi MS, Harrison PJ. Catechol- Omethyltransferase (COMT) and proline dehydrogenase (PRODH) mRNAs in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression. Synapse 2004; 51:112-118.
11. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996; 6:243-250.
12. Chen J, Lipska BK, Halim N, Ma QD, Matsumoto M, Melhem S, et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet 2004; 75:807-821.
13. Reuter M, Hennig J. Association of the functional catechol- Omethyltransferase VAL158MET polymorphism with the personality trait of extraversion. Neuroreport 2005; 16:1135-1138.
14. Kim SJ, Kim YS, Kim SY, Lee HS, Kim CH. An association study of catechol-O-methyltransferase and monoamine oxidase A polymorphisms and personality traits in Koreans. Neurosci Lett 2006; 401: 154-158.
15. Hashimoto R, Noguchi H, Hori H, Ohi K, Yasuda Y, Takeda M, et al. A possible association between the Val158Met polymorphism of the catechol-O-methyl transferase gene and the personality trait of harm avoidance in Japanese healthy subjects. Neurosci Lett 2007; 428:17-20.
16. Stein MB, Fallin MD, Schork NJ, Gelernter J. COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology 2005; 30:2092-2102.
17. Silberschmidt AL, Sponheim SR. Personality in relation to genetic liability for schizophrenia and bipolar disorder: differential associations with the COMT Val 108/158 Met polymorphism. Schizophr Res 2008; 100:316-324.
18. Gadow KD, Roohi J, DeVincent CJ, Kirsch S, Hatchwell E. Association of COMT (Val158Met) and BDNF (Val66Met) gene polymorphisms with anxiety, ADHD and tics in children with autism spectrum disorder. J Autism Dev Disord 2009; 39:1542-1551.
19. Hosak L. Role of the COMT gene Val158Met polymorphism in mental disorders: a review. Eur Psychiatry 2007; 22:276-281.
20. Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 2005; 10:765-770.
21. Okochi T, Ikeda M, Kishi T, Kawashima K, Kinoshita Y, Kitajima T, et al. Metaanalysis of association between genetic variants in COMT and schizophrenia: an update. Schizophr Res 2009; 110:140-148.
22. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75:843-854.
23. Bray NJ, Buckland PR,Williams NM,Williams HJ, Norton N, Owen MJ, et al. A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am J Hum Genet 2003; 73:152-161.
24. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, Lev-Lehman E, Weizman A, et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71:1296-1302.
25. Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry 1998; 155:1214-1220.
26. Hoda F, Nicholl D, Bennett P, Arranz M, Aitchison KJ, al-Chalabi A, et al. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochem Biophys Res Commun 1996; 228:780-784.
27. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36:D154-D158.
28. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004; 2:e363.
29. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120:15-20.
30. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, et al. A patternbased method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 2006; 126:1203-1217.
31. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R. Fast and effective prediction of microRNA/target duplexes. RNA 2004; 10:1507-1517.
32. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet 1955; 19:251-253.
33. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66:87-98.
34. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 2003; 19:149-150.
35. Jongeneel CV, Delorenzi M, Iseli C, Zhou D, Haudenschild CD, Khrebtukova I, et al. An atlas of human gene expression from massively parallel signature sequencing (MPSS). Genome Res 2005; 15:1007-1014.
36. Katayama S, Tomaru Y, Kasukawa T,Waki K, Nakanishi M, Nakamura M, et al. Antisense transcription in the mammalian transcriptome. Science 2005; 309:1564-1566.
37. Vandenbergh DJ, Rodriguez LA, Hivert E, Schiller JH, Villareal G, Pugh EW, et al. Long forms of the dopamine receptor (DRD4) gene VNTR are more prevalent in substance abusers: no interaction with functional alleles of the catechol-O-methyltransferase (COMT) gene. Am J Med Genet 2000; 96:678-683.
38. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, et al. Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 2000; 96:599-603.
39. Tiihonen J, Hallikainen T, Lachman H, Saito T, Volavka J, Kauhanen J, et al. Association between the functional variant of the catechol- Omethyltransferase (COMT) gene and type 1 alcoholism. Mol Psychiatry 1999; 4:286-289.
40. Wang T, Franke P, Neidt H, Cichon S, Knapp M, Lichtermann D, et al. Association study of the low-activity allele of catechol-O-methyltransferase and alcoholism using a family-based approach. Mol Psychiatry 2001; 6:109-111.
41. Beuten J, Payne TJ, Ma JZ, Li MD. Significant association of catechol-Omethyltransferase (COMT) haplotypes with nicotine dependence in male and female smokers of two ethnic populations. Neuropsychopharmacology 2006; 31:675-684.
42. Oosterhuis BE, LaForge KS, Proudnikov D, Ho A, Nielsen DA, Gianotti R, et al. Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women. Am J Med Genet B Neuropsychiatr Genet 2008; 147B:793-798.
43. Goldman-Rakic PS, ECr Muly,Williams GV. D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 2000; 31:295-301.
44. Zhou R, Yuan P,Wang Y, Hunsberger JG, Elkahloun A,Wei Y, et al. Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology 2009; 34:1395-1405.
45. Barnes MR, Deharo S, Grocock RJ, Brown JR, Sanseau P. The micro RNA target paradigm: a fundamental and polymorphic control layer of cellular expression. Expert Opin Biol Ther 2007; 7:1387-1399.